Abstract: A novel integration scheme is proposed for the accurate numerical evaluation of test (reaction) integrals needed for solving complex direct or inverse electromagnetic problems using surface ...
The myth of Donald Trump’s absolute power rests on everyone believing it’s true. So, hints of vulnerability, successful challenges to his authority, or portents of a not-so-distant future that he ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
If you are eyeing Vertex and wondering whether now is the right moment to jump in, you are not alone. The company has certainly grabbed attention lately. In just the last week, the stock moved up 2.4% ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
D ENIM IS DEMOCRACY, cut and stitched. It’s a fabric that belongs to everyone—no matter who you are or what you do. You’ll see it on the guy clocking miles on his bike before breakfast, the trainer ...
Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around 75,000 people with cystic fibrosis rely on Vertex Pharmaceuticals to keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback